Merck completed the acquisition of Cidara Therapeutics for $9.2bn.

Merck, a global healthcare company, completed the acquisition of Cidara Therapeutics, a biotechnology company, for $9.2bn. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet. CD388, a potentially first-in-class, long-acting antiviral with strain-agnostic properties, underscores that approach. We look forward to building on Cidara’s progress and further evaluating the potential of this candidate for the prevention of symptomatic influenza in certain individuals at high risk of complications,” Robert M. Davis, Merck Chairman and Chief Executive Officer.